TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03394638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to online eLearning module
Description: Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to online eLearning module
Description: Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to measurement devices
Description: Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional group
Description: All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional group
Description: All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
Study: NCT02272790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards.
Study: NCT01655160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MT with low-intensity group (MT-LI)
Description: The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
Study: NCT02272790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
Study: NCT02066064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-EYE(TM) Colonoscopy
Description: G-EYE(TM) Colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: G-EYE(TM) Colonoscopy
Description: G-EYE(TM) Colonoscopy
Study: NCT01569581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U/0.5ml in 6-11 months old infants
Description: inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U/0.5ml in 12-23 months old infants
Description: inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U/0.5ml in 24-35 months old children
Description: inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U/0.5ml in 36-71 months old children
Description: inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
Study: NCT00702143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi), single dose
Study: NCT04439890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin injection
Description: Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin injection
Description: Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
Study: NCT03872947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 5 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: 5 mg/kg administered intravenously over 60 minutes (weekly)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRK-950
Description: Treatment Phase: 20 mg/kg administered intravenously over 60 minutes (bi-weekly) Maintenance Phase: 30 mg/kg administered intravenously over 60 minutes (every 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenously over 30 - 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenously over 30 - 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenously over 30 - 90 minutes
Study: NCT01655160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MT with moderate-intensity group
Description: The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy with high intensity group
Description: The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
Study: NCT03872947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenously over 30 - 90 minutes
Study: NCT04439890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed disodium f Injection
Description: Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
Study: NCT03872947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intravenously bolus and intravenously for two days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intravenously bolus and intravenously for two days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenously per package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenously per package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenously per package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Intravenously over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Intravenously over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenously over 30 minutes
Study: NCT04418401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib and anti-PD-1 antibody
Description: Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
Study: NCT03996369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
Study: NCT04439890

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed disodium f Injection
Description: Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02901171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT group treatment combined with smartphone application
Description: The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT group treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group based Behavioural Support Programme
Description: The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
Study: NCT02800174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart nitinol stent implantation
Description: Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiplatelet drug
Description: Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
Study: NCT03996369

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
Study: NCT03814421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermittent (40mg as a bolus injection daily for 72hours)
Description: Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermittent (40mg as a bolus injection daily for 72hours)
Description: Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
Study: NCT00228215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPS Intervention
Description: A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
Study: NCT04711681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Behavior Supports in Middle Schools
Description: 2-4 days SWPBS training for school team and 1-2 days for whole staff training (SW and Classroom Management). Use staff release days for whole staff training.~Schedule up to four meetings with the PBS team~1K/School is to fund part or whole day training meeting with PBS team Schedule whole staff training per school year staff release days Enhanced Intervention Family Support Universal -- parent education and invitation Selective -- Family Check up School Intervention ACT for teachers PBS Calendar Kernel Recipes (Treatment) Reminder Emails Brochures Weekly phone contact (Treatment)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Behavior Supports in Middle Schools
Description: 1 days PBS training for school team and informational presentation to whole staff Attend 2-3 PBS team meetings (coaching) Data-based feedback (limited)
Study: NCT02954315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Study: NCT03356704

Intervention type: OTHER
Intervention: no intervention
Description: Observational study

Intervention type: OTHER
Intervention: no intervention
Description: Observational study
Study: NCT00372918

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transnasal Esophagoscopy
Description: fiberoptic exam of esophagus thru nares
Study: NCT03356704

Intervention type: OTHER
Intervention: no intervention
Description: Observational study
Study: NCT00912561

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intense aerobic exercise
Description: 3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
Study: NCT03872947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenously over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously over 30 minutes
Study: NCT01655160

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention group
Description: The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
Study: NCT03785028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: working memory and attention
Description: working memory and attention tasks
Study: NCT02341469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated ediagnostic approach (IeDA)
Description: IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:~* REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.~* The training of nurses on IMCI and REC.~* A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.~* A supervision system conducted implemented by district managers to provide support and guidance to health centres.~* A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres.
Study: NCT00793273

Intervention type: DRUG
Intervention: insulin detemir
Description: Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
Study: NCT03271983

Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole gel 1
Description: RLD gel

Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole gel 2
Description: generic gel

Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole cream
Description: generic cream
Study: NCT04678076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen Lysine
Description: A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen Oral Product
Description: A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
Study: NCT01246908

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered twice per day for six weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX157 (TriRima)
Description: One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
Study: NCT03740984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.
Description: During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.
Description: During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.
Description: During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
Study: NCT01319331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha 1-Antitrypsin (AAT, Aralast NP)
Description: Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
Study: NCT04081259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
Study: NCT00606047

Intervention type: RADIATION
Intervention: Magnetic resonance imaging (MRI)
Description: Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
Study: NCT01565304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER Through Choices
Description: 10-session group-based sexual education curriculum
Study: NCT04386941

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Xpeeda Fibre Laser Vaporesection of the Prostate
Description: Both interventions are currently used standard of care treatments for the Holmium laser enucleation of the prostate (HoLEP) for patients with bothersome lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).~Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue.